Conducted financial and precedent transaction analysis to assist in the evaluation of deal terms for equity and debt term sheets ​

Integral in negotiating economic and non-economic terms and provided guidance to Rapid Micro throughout the transaction process

Successful Outcome

Rapid Micro successfully raised an equity financing round ($60M) led by new investors Bain Capital Life Sciences and Xeraya Capital​

The new funding round also included an investment from a new strategic player, Asahi Kasei Medical, along with continued participation by Longitude Capital, Quaker Partners, TVM Capital, and Richard K. Mellon and Sons​

Funding will be used to accelerate global commercial expansion, operational capability and product innovation​

Rapid Micro has continued discussions with strategics to explore co-promotion and commercial partnership opportunities to support its growth initiatives